TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung, Michael P Osborn, Deborah L White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K Hiwase, Mark Hertzberg, Anthony P Schwarer, Robin Filshie, Christopher K Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J Forsyth, John Taper, David M Ross, Jennifer Beresford, Constantine Tam Show all
Blood | AMER SOC HEMATOLOGY | Published : 2015
This work was supported in part by grants from Novartis Pharmaceuticals Australia. This study was sponsored by the Australasian Leukaemia and Lymphoma Group. D.T.Y. is a PhD candidate at the University of Adelaide and this work is submitted in partial fulfillment of the requirement for the PhD. D.T.Y. receives PhD scholarship funding from the Leukaemia Foundation of Australia and the Royal Adelaide Hospital Research Foundation A. R. Clarkson Scholarship. D.T.Y. received a Clinical Research Training Institute training award from the American Society of Hematology. T.P.H. is a National Health and Medical Research Council Practitioner Fellow. Novartis has no role in gathering, analyzing, or interpreting the data.